-64.5%
ADBE vs MRNA
+153.9%
-218.4%
-69.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.8% | -2.2% | +0.4% | -1.7% |
| 7D | -10.4% | -12.7% | +2.3% | -10.2% |
| 30D | -14.6% | -20.7% | +6.0% | -14.3% |
| 3M | -20.0% | +46.3% | -66.3% | -21.0% |
| 6M | -14.1% | +305.2% | -319.3% | -19.6% |
| YTD | -37.8% | +561.2% | -599.0% | -43.7% |
| 1Y | -30.3% | +772.1% | -802.4% | -38.1% |
| 3Y | -64.5% | +147.0% | -211.4% | -65.8% |
| All | -64.5% | +153.9% | -218.4% | -65.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling